FDA Clears New COVID-19 Vaccine Option From Novavax for Adults
Headline from NBC4 Washington, on the newest of 2 developments
Nearly a quarter of American adults still haven't gotten their primary vaccinations even this late in the pandemic, and experts expect at least some of them to roll up their sleeves for a more conventional option — a protein-based vaccine.
NBC4 Washington's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Administration secures 3.2 million doses of Novavax COVID-19 vaccine
Headline from Health Care Finance News ·
Newest
FDA Clears New COVID-19 Vaccine Option From Novavax for Adults
The Department of Health and Human Services said the U.S. will order more than 3 million doses of Novavax, Inc. COVID-19 vaccine upon emergency authorization.
The US Food and Drug Administration on Wednesday authorized Novavax's Covid-19 vaccine for emergency use in adults. It is the fourth coronavirus vaccine available in the United States, and it uses a different type of vaccine technology than the shots already available.
The U.S. Food and Drug Administration authorized the use of Novavax Inc’s COVID-19 vaccine on Wednesday, clearing the way for a shot whose more traditional technology has raised hopes of
Experts expect at least some of those who remain unvaccinated to roll up their sleeves for the Novavax shot because it's a more conventional protein-based vaccine.
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S. -- and one that’s already available in Europe and multiple other countries.
Unlike Moderna's and Pfizer-BioNTech's mRNA vaccine, Novavax's vaccine was created using a trace amount of the COVID spike protein, resulting in immune response from the human body, which is boosted by another substance.
The U.S. is getting another COVID-19 vaccine choice. The Food and Drug Administration on Wednesday cleared Novavax shots for adults. It's a more traditional type of vaccine than the Pfizer
Novavax’s vaccine uses an older technology found in other widely used shots, offering people an alternative to the mRNA-based Pfizer and Moderna vaccines.
Nearly a quarter of American adults still haven't gotten their primary vaccinations even this late in the pandemic, and experts expect at least some of them to roll up their sleeves for a more conventional option — a protein-based vaccine.
The Food and Drug Administration has authorized use of the two-dose Novavax COVID-19 vaccine for adults 18 and over, making it the fourth vaccine to be made available since the pandemic began nearly two years ago.
